Oncoimmunology

Article	Citations
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	97
In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages	92
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	89
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	67
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	61
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	59
Ferroptosis: friend or foe in cancer immunotherapy?	57
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	57
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	56
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	54
STING is significantly increased in high-grade glioma with high risk of recurrence	49
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	48
Correction	44
FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation	43
Radiotherapy-induced abscopal effects in immune checkpoint inhibitor-refractory metastatic disease: results from a large multicenter real-world cohort study	40
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	40
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models	40
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	40
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	38
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	37
Mild microwave hyperthermia promotes mitotic catastrophe, induces time-delayed cGAS-STING activation and restores sensitivity to anti-PDL1 therapy in Pan02 pancreatic cancer model	36
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	36
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	35
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	33
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	33

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer	32
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	32
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	32
Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research	30
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	30
KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma	30
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	30
Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer	30
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	30
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases	29
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	29
Cell therapy for a rare disease- hairy cell leukemia variant	29
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	29
Immune cell clustering identifies a CD163⁺/CSF1R⁺ macrophage and neutrophil-enriched phenotype with distinct biological signatures and poor prognosis in angiosarcoma	29
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab	29
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	28
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread	28
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML	27
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis	27
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling	26
Tumor-infiltrating B cells produce tumor-specific antibodies and may contribute to suppressing tumor in head and neck squamous cell carcinoma	26
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	25
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8 + T cells towards the center of human lung tumors	25
Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells	25
Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer	25
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer	24
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion	24
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 + T cell function	24
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	24
Trial watch: beta-blockers in cancer therapy	23
The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology	23
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	22
Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice	22
The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment	22
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)	22
Cancer associated fibroblast–T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC)	21
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes	21
Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue	21
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers	21
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response	21
Schweinfurthin induces ICD without ER stress and caspase activation	21
Candidate tumor-specific CD8 + T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis	21
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia	21
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	21
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	20
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	20
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	20
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	20
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 + T cells in vivo	20
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer	20

CD8 + T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance	20
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	20
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products	20
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma	19
FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer	19
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	19
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	19
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	19
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy	19
Cell type-specific induction of ferroptosis to boost antitumor immunity	18
Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids	18
Piezo1 facilitates optimal T cell activation during tumor challenge	18
IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy	18
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	18
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	18
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	17
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	17
Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma	17
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	17
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	17
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	17
Non-pharmaceutical interventions to optimize cancer immunotherapy	17
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors	17
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis	17
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	17
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	17
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis	16
Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma	16
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity	16
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	16
Arsenic trioxide as an inducer of immunogenic cell death	16
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands	16
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	16
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis	15
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death	15
CD4 + tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	15
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?	15
How macrophages use extracellular calreticulin to chase their prey	15
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function	15
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses	15
Correction	15
Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8 + T cells	15
Early local immune activation following intra-operative radiotherapy in human breast tissue	14
The landscape of T-cell engagers for the treatment of follicular lymphoma	14
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases	14
Metabolic regulation of the mitochondrial immune checkpoint	14
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival	14
Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts	14
Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer	14
An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer	14
Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models	14
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I int	13
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors	13
Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment	13
CD25 bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression	13
Type I interferon induces cancer stem cells-mediated chemotherapy resistance	13
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies	13
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	13
Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer	13
EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity	13
Cross-disease integration of single-cell RNA sequencing data from lung myeloid cells reveals TAM signature in in vitro model	13
Immunotherapy approaches for the treatment of diffuse midline gliomas	12
The double face of IL-1β in lung cancer	12
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma	12
ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer	12
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	12
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin	12
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor	12
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site	12
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma	12
Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137	12
Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma	12
Cellular senescence enhances adaptive anticancer immunosurveillance	12
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases	12
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody	12
Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion	12
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function	12
Leptin decreases Th17/Treg ratio to facilitate neuroblastoma via inhibiting long-chain fatty acid catabolism in tumor cells	12
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)	12
A mitochondrial checkpoint to adaptive anticancer immunity	12

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma	11
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	11
PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy	11
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma	11
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer	11
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome	11
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes	11
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma	11
Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma	11
Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression	11
Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics	11
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study	11
Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs	10
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	10
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells	10
An oncogene regulating chromatin favors response to immunotherapy	10
Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human	10
ADA/CD26 axis increases intra-tumor PD-1 + CD28 + CD8 + T-cell fitness and affects NSCLC progno	10
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome	10
Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression	10
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy	10
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv	10
A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy	10
Pharmacological inhibition of MAPK P38α rescues the immune defect of dendritic cells affected by the FPR1 loss-of-function polymorphism rs867228	10
Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response	10
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells	10
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors	10
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer	10
2025 List of Reviewers for OncoImmunology	10
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor	10
CD4 + cell depletion accelerates dendritic cell migration and enhances resident dendritic cell pro	9
Immune modulation following α and β − radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model	9
Smad7 is a negative regulator of immunogenic cell death in colorectal cancer	9
Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients	9
A role for EMT in CD73 regulation in breast cancer	9
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment	9
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy	9
Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody	9
C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer	9
Correction	9
CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy	9
Eribulin mesylate exerts antitumor effects via CD103	9
Paradoxical control of multifocal mammary oncogenesis by radiation therapy	9
S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs	9
Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer	9
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma	9
Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells	9
Correction	9
RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism	9
Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine	9
IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells	9
Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma	9
Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes	9
Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer	8
Targeting the atypical chemokine receptor 2 ( Ackr2 ) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model	8
Principles of risk assessment in colon cancer: immunity is key	8
Studying TIGIT activity against tumors through the generation of knockout mice	8
RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug	8
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes	8
Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment	8
Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypes	8
T-cell dysfunction in natural killer/T-cell lymphoma	8
Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies	8
NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo ,	8
Anti-CD122 antibody restores specific CD8 + T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth	8
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease	8
Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers	8
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies	8
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer	8
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression	8
HLA class II neoantigen presentation for CD4 + T cell surveillance in HLA class II-negative colorectal cancer	8
A laminin α4–CD8 + T cell axis shapes the prognostic impact of macrophages and regulatory T cells in early-stage colorectal cancer	8
Dectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer	8
The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis	8
High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy	8
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis	8
Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor	8
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models	8
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses	8
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer	7
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	7
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma	7
Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2 , and CD44 through NFκB-signal	7
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies	7
Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escape	7
Correction	7
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid	7
Correction	7
Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance	7
Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer	7
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses	7
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities	7
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles	7
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	7
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint in	7